close

Agreements

1 207 208 209 210 211 246
Number of results: 4911

PDF print is not allowed for data more than 3000.Please search above for fewer data.

Date Company Compound Disease Type of agreement Therapeutic area Type of Information
2012-11-28 Evotec (Germany) Probiodrug (Germany) assays to support the pre-clinical and clinical development of glutaminyl cyclase (QC) inhibitors for the treatment of Alzheimer’s disease Alzheimer’s disease collaboration
services
Neurodegenerative diseases
2012-11-28 Beactica (Sweden) Janssen Research & Development - J&J (Belgium-USA) Sprint™ undisclosed

R&D
collaboration
services

undisclosed R&D agreement
2012-11-28 Sanofi (France) Selecta Biosciences (USA) antigen-specific immunotherapies life-threatening allergies

R&D
licensing

Allergic diseases - Immunological diseases R&D agreement
2012-11-28 Hovione (Portugal) Solvias (Switzerland) pharmaceutical co-crystals

collaboration
services

Collaboration agreement
2012-11-27 Mundipharma (UK) Northlake International (USA) Hangzhou Minsheng Pharmaceutical (China) NL-101 and back-up molecules haematological malignancies

R&D
development
licensing
commercialisation

Cancer - Oncology R&D agreement
2012-11-23 UCB (Belgium) Exemed Pharmaceuticals (India)

manufacturing
production

Production agreement
2012-11-23 Orphan Europe, part of Recordati Group (Italy) Erytech (France) Graspa® (L-asparaginase encapsulated in red blood cells, using technology owned by Erytech Pharma) acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML)

licensing

Cancer - Oncology Licensing agreement
2012-11-22 Activiomics (UK) Kyowa Hakko Kirin (Japan) TIQUAS (Targeted In-depth QUAntification of cell Signaling) phosphoproteomics platform

R&D

R&D agreement
2012-11-22 In-Cell-Art (France) Delta-Vir (Germany) In-Cell-Art ICANtibodies™ technology

collaboration
R&D

Cancer - Oncology Collaboration agreement
2012-11-21 Ablynx (Belgium) Algeta (Norway) alpha-pharmaceuticals comprising thorium-227 conjugated to tumor-targeting Nanobodies®

R&D

Cancer - Oncology R&D agreement
2012-11-20 Shire (UK) Boston Children’s Hospital (USA) undisclosed rare pediatric diseases with high unmet medical need

R&D

Rare diseases R&D agreement
2012-11-19 Bavarian Nordic (Denmark) U.S. Department of Homeland Security (DHS - USA) Science and Technology Directorate - National Institutes of Health (NIH - USA) recombinant Modified Vaccinia virus Ankara (MVA)-based vaccines including MVA-BN®-based human vaccine against the viral hemorrhagic fever Marburg and MVA-BN®-based animal vaccine against Foot-and-mouth disease viral hemorrhagic fever Marburg, Foot-and-mouth disease

development

Infectious diseases Development agreement
2012-11-15 bioMérieux (France) Quanterix (USA) Simoa (Single MOlecule Array) technology Simoa™ technology (named for single molecule array) is based upon the isolation of individual immunocomplexes on paramagnetic beads using standard ELISA reagents. This digital approach enables detection of a signal from single molecules of a labelled analyte, and is much more sensitive than conventional analog-based protein detection technologies. The main difference between Simoa and conventional immunoassays lies in the ability to trap single molecules in femtoliter-sized wells, allowing for a “digital” readout of each individual bead to determine if it is bound to the target analyte or not. The digital nature of the technique allows an average of 1000x sensitivity increase over conventional assays with CVs <10%.


licensing

Licensing agreement
2012-11-14 biOasis Technologies (Canada) MedImmune (USA - global biologics arm of AstraZeneca (UK) Transcend technology Transcend technology is based on p97 (melanotransferrin). p97 can be used to deliver therapeutics agents through the Blood Brain Barrier (BBB). Brain capillaries, that comprise the BBB, possess an endogenous receptor that ferries an iron-transport protein, termed p97 (melanotransferrin), across the BBB.

R&D

R&D agreement
2012-11-14 GSK (UK) Alacris Theranostics (Germany) ModCell™ System

R&D

Cancer - Oncology R&D agreement
2012-11-13 Transgene (France) EORTC (EU) TG4001 HPV16 positive oropharyngeal squamous cell carcinoma

clinical research

Cancer - Oncology Clinical research agreement
2012-11-13 Vivalis (France) undisclosed partner EB66® cell line

licensing

Cancer - Oncology Licensing agreement
2012-11-13 Tigenix (Belgium) Genpharm Services (Dubai - United Arab Emirates) ChondroCelect® symptomatic cartilage defects of the knee

commercialisation
distribution

Bone diseases Commercialisation agreement
2012-11-13 Aptuit (USA) GSK (UK)

R&D

R&D agreement
2012-11-13 Catalent Pharma Solutions (USA) Cevec Pharmaceuticals (Germany) recombinant human alpha-1 antitrypsin (hAAT) - CAP® cell line - GPEx® technology

development
commercialisation
promotion

Development agreement